Considerations on antimicrobial prophylaxis in patients with lymphoproliferative diseases: A SEIFEM group position paper

SEIFEM (Sorveglianza Epidemiologica delle InFezioni nelle EMopatie)

doi:10.1016/j.critrevonc.2020.103203

Considerations on antimicrobial prophylaxis in patients with lymphoproliferative diseases: A SEIFEM group position paper

SEIFEM (Sorveglianza Epidemiologica delle InFezioni nelle EMopatie)

Istituto Regina Elena

Research output: Contribution to journal › Review article › peer-review

Abstract

The therapeutic armamentarium for the treatment of patients with lymphoproliferative diseases has grown considerably over the most recent years, including a large use of new immunotherapeutic agents. As a consequence, the epidemiology of infectious complications in this group of patients is poorly documented, and even more importantly, the potential benefit of antimicrobial prophylaxis remains a matter of debate when considering the harmful effect from the emergence of multidrug resistant pathogens. The present position paper is addressed to all hematologists treating patients affected by lymphoproliferative malignancies with the aim to provide clinicians with a useful tool for the prevention of bacterial, fungal and viral infections.

Original language	English
Pages (from-to)	103203
Journal	Critical Reviews in Oncology/Hematology
Volume	158
DOIs	https://doi.org/10.1016/j.critrevonc.2020.103203
Publication status	Published - Feb 2021

Keywords

Anti-Bacterial Agents/therapeutic use
Anti-Infective Agents/therapeutic use
Humans
Lymphoproliferative Disorders/drug therapy

Access to Document

10.1016/j.critrevonc.2020.103203

Fingerprint Dive into the research topics of 'Considerations on antimicrobial prophylaxis in patients with lymphoproliferative diseases: A SEIFEM group position paper'. Together they form a unique fingerprint.

Cite this

@article{5d59ed444c264dfd9d05820ad50b9396,

title = "Considerations on antimicrobial prophylaxis in patients with lymphoproliferative diseases: A SEIFEM group position paper",

abstract = "The therapeutic armamentarium for the treatment of patients with lymphoproliferative diseases has grown considerably over the most recent years, including a large use of new immunotherapeutic agents. As a consequence, the epidemiology of infectious complications in this group of patients is poorly documented, and even more importantly, the potential benefit of antimicrobial prophylaxis remains a matter of debate when considering the harmful effect from the emergence of multidrug resistant pathogens. The present position paper is addressed to all hematologists treating patients affected by lymphoproliferative malignancies with the aim to provide clinicians with a useful tool for the prevention of bacterial, fungal and viral infections.",

keywords = "Anti-Bacterial Agents/therapeutic use, Anti-Infective Agents/therapeutic use, Humans, Lymphoproliferative Disorders/drug therapy",

author = "{SEIFEM (Sorveglianza Epidemiologica delle InFezioni nelle EMopatie)} and Alessandro Busca and Chiara Cattaneo and {De Carolis}, Elena and Gianpaolo Nadali and Massimo Offidani and Marco Picardi and Anna Candoni and Eleonora Ceresoli and Marianna Criscuolo and Mario Delia and {Della Pepa}, Roberta and {Del Principe}, Ilaria and Fanci, {Roma Rosa} and Francesca Farina and Nicola Fracchiolla and Claudia Giordano and Michele Malagola and Francesco Marchesi and Monica Piedimonte and Lucia Prezioso and Quinto, {Angela Maria} and Angelica Spolzino and Tisi, {Maria Chiara} and Fabio Trastulli and Trecarichi, {Enrico Maria} and Patrizia Zappasodi and Mario Tumbarello and Livio Pagano",

note = "Copyright {\textcopyright} 2020. Published by Elsevier B.V.",

year = "2021",

month = feb,

doi = "10.1016/j.critrevonc.2020.103203",

language = "English",

volume = "158",

pages = "103203",

journal = "Critical Reviews in Oncology/Hematology",

issn = "1040-8428",

publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - Considerations on antimicrobial prophylaxis in patients with lymphoproliferative diseases

T2 - A SEIFEM group position paper

AU - SEIFEM (Sorveglianza Epidemiologica delle InFezioni nelle EMopatie)

AU - Busca, Alessandro

AU - Cattaneo, Chiara

AU - De Carolis, Elena

AU - Nadali, Gianpaolo

AU - Offidani, Massimo

AU - Picardi, Marco

AU - Candoni, Anna

AU - Ceresoli, Eleonora

AU - Criscuolo, Marianna

AU - Delia, Mario

AU - Della Pepa, Roberta

AU - Del Principe, Ilaria

AU - Fanci, Roma Rosa

AU - Farina, Francesca

AU - Fracchiolla, Nicola

AU - Giordano, Claudia

AU - Malagola, Michele

AU - Marchesi, Francesco

AU - Piedimonte, Monica

AU - Prezioso, Lucia

AU - Quinto, Angela Maria

AU - Spolzino, Angelica

AU - Tisi, Maria Chiara

AU - Trastulli, Fabio

AU - Trecarichi, Enrico Maria

AU - Zappasodi, Patrizia

AU - Tumbarello, Mario

AU - Pagano, Livio

PY - 2021/2

Y1 - 2021/2

N2 - The therapeutic armamentarium for the treatment of patients with lymphoproliferative diseases has grown considerably over the most recent years, including a large use of new immunotherapeutic agents. As a consequence, the epidemiology of infectious complications in this group of patients is poorly documented, and even more importantly, the potential benefit of antimicrobial prophylaxis remains a matter of debate when considering the harmful effect from the emergence of multidrug resistant pathogens. The present position paper is addressed to all hematologists treating patients affected by lymphoproliferative malignancies with the aim to provide clinicians with a useful tool for the prevention of bacterial, fungal and viral infections.

AB - The therapeutic armamentarium for the treatment of patients with lymphoproliferative diseases has grown considerably over the most recent years, including a large use of new immunotherapeutic agents. As a consequence, the epidemiology of infectious complications in this group of patients is poorly documented, and even more importantly, the potential benefit of antimicrobial prophylaxis remains a matter of debate when considering the harmful effect from the emergence of multidrug resistant pathogens. The present position paper is addressed to all hematologists treating patients affected by lymphoproliferative malignancies with the aim to provide clinicians with a useful tool for the prevention of bacterial, fungal and viral infections.

KW - Anti-Bacterial Agents/therapeutic use

KW - Anti-Infective Agents/therapeutic use

KW - Humans

KW - Lymphoproliferative Disorders/drug therapy

U2 - 10.1016/j.critrevonc.2020.103203

DO - 10.1016/j.critrevonc.2020.103203

M3 - Review article

C2 - 33388453

VL - 158

SP - 103203

JO - Critical Reviews in Oncology/Hematology

JF - Critical Reviews in Oncology/Hematology

SN - 1040-8428

ER -